Resultados da busca - Eva Muñoz‐Couselo

Refinar Resultados
  1. 1
    Targeting FGFR pathway in breast cancer

    Targeting FGFR pathway in breast cancer por José Manuel Pérez-García, Eva Muñoz‐Couselo, Jesús Soberino, Fabricio Racca, Javier Cortés

    Publicado em 2017
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  2. 2
    <em>NRAS</em>-mutant melanoma: current challenges and future prospect

    <em>NRAS</em>-mutant melanoma: current challenges and future prospect por Eva Muñoz‐Couselo, Esther Zamora, Carolina Ortiz, Jesús Soberino-García, José Manuel Pérez-García

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  3. 3
    Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?

    Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies? por Mar Riveiro‐Barciela, Eva Muñoz‐Couselo, Jesús Fernández‐Sojo, Nely Díaz‐Mejía, Rafael Parra-López, Marı́a Buti

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Carta
    Salvar na lista
    Na minha lista:
  4. 4
    A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy

    A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy por Adriana Sánchez‐Danés, Jean‐Christophe Larsimont, Mélanie Liagre, Eva Muñoz‐Couselo, Gaëlle Lapouge, Audrey Brisebarre, Christine Dubois, Mariano Suppa, Vijayakumar Sukumaran, V. del Mármol, Josep Tabernero, Cédric Blanpain

    Publicado em 2018
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  5. 5
    Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

    Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 stud... por Peter Schmid, Roberto Salgado, Y.H. Park, Eva Muñoz‐Couselo, S.B. Kim, Joohyuk Sohn, Seock‐Ah Im, Theodoros Foukakis, Sherko Küemmel, Rebecca Dent, Lei Yin, A. Wang, Konstantinos Tryfonidis, Vassiliki Karantza, Javier Cortés, Sherene Loi

    Publicado em 2020
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  6. 6
    Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

    Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial por Brett Hughes, Eva Muñoz‐Couselo, Laurent Mortier, Å. Bratland, Ralf Gutzmer, Osama Roshdy, René González Mendoza, Jacob Schachter, Ana Arance, Florent Grange, Nicolás Meyer, Abhishek Joshi, Salem Billan, P. Zhang, Burak Gümüşçü, Ramona F. Swaby, Jean‐Jacques Grob

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  7. 7
    Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

    Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab por Omid Hamid, Luciana Molinero, Christopher R. Bolen, Jeffrey A. Sosman, Eva Muñoz‐Couselo, Harriet M. Kluger, David F. McDermott, John D. Powderly, Indrani Sarkar, Marcus Ballinger, Marcella Fassò, Carol O’Hear, Daniel S. Chen, Priti S. Hegde, F. Stephen Hodi

    Publicado em 2019
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  8. 8
    Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations

    Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti... por Paolo A. Ascierto, Petri Bono, Shailender Bhatia, Ignacio Melero, Marta Nyakas, Inge Marie Svane, James Larkin, Carlos Gomez‐Roca, Dirk Schadendorf, R. Dummer, Aurélien Marabelle, Christoph Höeller, Mark Maurer, Christopher Harbison, Priyam Mitra, Satyendra Suryawanshi, Kent Thudium, Eva Muñoz‐Couselo

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  9. 9
    1473 Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-001 clinical trial

    1473 Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-00... por Célèste Lebbé, Shruthi Ravimohan, Antara Datta, Aparna Chhibber, Eva Muñoz‐Couselo, Caio Guilherme Pereira, Shahneen Sandhu, Ming Zhou, Brendan D. Curti, Nikhil I. Khushalani, Matthew Taylor, Alfonsus Van Den Eertwegh, Ute Hoch, Georgina Long AO, Yull Arriaga, Adi Diab, Helen Gogas

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  10. 10
    Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study

    Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of th... por Rebecca Dent, Javier Cortés, Yeon Hee Park, Eva Muñoz‐Couselo, Sung‐Bae Kim, Joohyuk Sohn, Seock‐Ah Im, Esther Holgado, Theodoros Foukakis, Sherko Kümmel, Jennifer H. Yearley, Anran Wang, Michael Nebozhyn, Lingkang Huang, Rǎzvan Cristescu, Petar Jelinic, Vassiliki Karantza, Peter Schmid

    Publicado em 2025
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  11. 11
    785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)

    785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL) por Adi Diab, Helen Gogas, Shahneen Sandhu, Georgina V. Long, Paolo A. Ascierto, James Larkin, Mario Sznol, Fábio Franke, T. Ciuleanu, Eva Muñoz‐Couselo, A. Perfetti, Célèste Lebbé, Friedegund Meier, Brendan D. Curti, C. Rojas, Hwai‐I Yang, Ming Zhou, Shruthi Ravimohan, Mary Tagliaferri, N. Khushanlani

    Publicado em 2022
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  12. 12
    A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

    A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-... por Sarah A. Weiss, Mario Sznol, Montaser Shaheen, Miguel‐Ángel Berciano‐Guerrero, Eva Muñoz‐Couselo, Delvys Rodríguez‐Abreu, Valentina Boni, Lynn M. Schuchter, María González‐Cao, Ana Arance, Wei Wei, Apar Kishor Ganti, Ralph J. Hauke, Alfonso Berrocal, Nicholas Iannotti, Frank J. Hsu, Harriet M. Kluger

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  13. 13
    An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury

    An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury por Mar Riveiro‐Barciela, Ana Barreira‐Díaz, María‐Teresa Salcedo, Ana Callejo, Eva Muñoz‐Couselo, Patricia Iranzo, Carolina Ortiz, S. Cedrés, Nely Díaz‐Mejía, J. Cobo, Rafael Morales, Juan Aguilar‐Company, Esther Zamora, Mafalda Oliveira, María‐Teresa Sanz‐Martínez, L Viladomiu, Mónica Martínez‐Gallo, Enriqueta Felip, Marı́a Buti

    Publicado em 2024
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  14. 14
    Five latent factors underlie response to immunotherapy

    Five latent factors underlie response to immunotherapy por Joseph Usset, Axel K.M. Rosendahl Huber, Maria Andrianova, Eduard Batlle, Joan Carles, Edwin Cuppen, Elena Élez, Enriqueta Felip, Marina Gómez-Rey, Deborah Lo Giacco, Francisco Martínez-Jiménez, Eva Muñoz‐Couselo, Lillian L. Siu, Josep Tabernero, Ana Vivancos, Ferran Muiños, Abel González-Pérez, Núria López-Bigas

    Publicado em 2024
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  15. 15
    Adjuvant Therapy Versus Watch-and-Wait Post Surgery for Stage III Melanoma: A Multicountry Retrospective Chart Review

    Adjuvant Therapy Versus Watch-and-Wait Post Surgery for Stage III Melanoma: A Multicountry Retrospective Chart Review por Peter Mohr, Felix Kiecker, Vincent Soriano, O. Dereure, Karmele Mujika, Philippe Saïag, Jochen Utikal, Rama Koneru, Caroline Robert, F. Perez Cuadros, Matías Chacón, Rodrigo U. Villarroel, Yana G. Najjar, Lisa A. Kottschade, Eva Muñoz‐Couselo, Roy Koruth, Annie Guérin, Rebecca Burne, Raluca Ionescu‐Ittu, Maurice Perrinjaquet, Jonathan S. Zager

    Publicado em 2019
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  16. 16
    2314P Quality and safety of research biopsies (RB) in oncology clinical trials

    2314P Quality and safety of research biopsies (RB) in oncology clinical trials por Paolo Nucíforo, Fiorella Ruíz‐Pace, J. Jiménez, Raquel Comas, R. Fasani, Cristina Viaplana, C. Sevillano, Pablo Martínez, X Serres i Créixams, C. Saura Manich, M.E. Elez Fernandez, Ana Oaknin, Irene Braña, Eva Muñoz‐Couselo, Teresa Macarulla, J. Carles Galceran, Josep Tabernero, Enriqueta Felip, Elena Garralda, Rodrigo Dienstmann

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  17. 17
    Contribution of tumour and immune cells to <scp>PD‐L1</scp> expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from <scp>KEYNOTE</scp>‐119

    Contribution of tumour and immune cells to <scp>PD‐L1</scp> expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from <scp>KEYNOTE... por Javier Cortés, Eric P. Winer, O. N. Lipatov, Seock‐Ah Im, Anthony Gonçalvès, Eva Muñoz‐Couselo, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Stephanie Hund, Karina Kulangara, Vassiliki Karantza, Jaime Mejia, Junshui Ma, Petar Jelinic, Lingkang Huang, Scott K. Pruitt, Kenneth Emancipator

    Publicado em 2024
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  18. 18
    Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020

    Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy... por Paolo A. Ascierto, Hao Tang, Sonia Dolfi, Marta Nyakas, Inge Marie Svane, Eva Muñoz‐Couselo, Jean‐Jacques Grob, Carlos Gomez‐Roca, Vanna Chiarion‐Sileni, Katriina Peltola, James Larkin, Ignacio Melero, Margaret K. Callahan, Reinhard Dummer, Patrick Djidel, Deepti Warad, Diane Reusser-Wolf, Evan J. Lipson, Charlie Garnett‐Benson

    Publicado em 2025
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  19. 19
    Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies

    Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies por Azad Saei, Marta Palafox, Touati Benoukraf, Nishi Kumari, Patrick Jaynes, Prasanna Vasudevan Iyengar, Eva Muñoz‐Couselo, Paolo Nucíforo, Javier Cortés, Christopher Nötzel, Nesaretnam Barr Kumarakulasinghe, John Lalith Charles Richard, Zul Fazreen Bin Adam Isa, Brendan Pang, Marta Guzmán, Siqin Zhou, Henry Yang, Wai Leong Tam, Violeta Serra, Pieter J.A. Eichhorn

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  20. 20
    Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics

    Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics por Maria Lozano-Rabella, Andrea García-Garijo, Jara Palomero, Anna Yuste-Estevanez, Florian Erhard, Roc Farriol-Duran, Juan Martín-Liberal, Maria Ochoa de Olza, Ignacio Matos, Jared J. Gartner, Michael Ghosh, Francesc Canals, August Vidal, Josep M. Piulats, Xavier Matías‐Guiu, Irene Braña, Eva Muñoz‐Couselo, Elena Garralda, Andreas Schlösser, Alena Gros

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Carta
    Salvar na lista
    Na minha lista:

Ferramentas de busca: